Although the 4T1 breast carcinoma model is not optimal for studying adaptive antitumor immunity, the synergy between CD47 blockade and chemotherapy response in this model suggests the relevance of CD47 as a therapeutic target for overcoming treatment resistance in breast cancer [11]. This evidence concerns the gene CD47 and breast carcinoma.